College of San Mateo

Recent papers from College of San Mateo

1. Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating PeptidesInternational Journal of Molecular Sciences · 2026
2. Associations among caregiving burden, social support, hope, mastery, and depressive symptoms in family caregivers of children and young people with mental illness: a chain mediation analysisBMC Psychiatry · 2026
3. Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 StudyCancer Research Communications · 2026
4. Untangling Surfaces via Shape and Mesh RepulsionACM Transactions on Graphics · 2026
5. Safety of Less Invasive Surfactant Administration in Preterm Infants: A Meta‐AnalysisPediatric Pulmonology · 2026
6. Trace-Guided Synthesis of Effectful Test GeneratorsProceedings of the ACM on Programming Languages · 2025
7. Translational bottlenecks in blood-based proteomicsEMBO Molecular Medicine · 2026
8. A phase I, multi-center study of KIVU-107, a novel PTK7-targeting antibody-drug conjugate (ADC), in participants with advanced solid tumors.Journal of Clinical Oncology · 2026
9. Utilizing large language models for lung cancer patient education compared to publicly available information.Journal of Clinical Oncology · 2026
10. Digital information–seeking behavior in patients with cancer through storytelling.Journal of Clinical Oncology · 2026
11. Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled TrialAmerican Journal of Psychiatry · 2026
12. Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areataSHILAP Revista de lepidopterología · 2026
13. Abstract 6922: BHB810: A novel site-specific CDH17-directed VHH-Fc ADC for gastric cancerCancer Research · 2026
14. Abstract 5649: KIVU-107: A clinical-stage, best-in-class PTK7 antibody-drug conjugate (ADC) with favorable PK and an improved tolerability profile.Cancer Research · 2026
15. Abstract 4411: Discovery of mutation-independent cKit degrading bispecific antibodies that suppress tumor growth in preclinical models of GISTCancer Research · 2026
16. Abstract 4051: BHB299: An AI/ML-optimized high avidity/low affinity CEACAM6-directed T cell engager for diverse solid tumorsCancer Research · 2026
17. Abstract 5648: Preclinical efficacy and safety of KIVU-305, a novel CEACAM5-targeting antibody-drug conjugate (ADC) for colorectal cancer (CRC).Cancer Research · 2026
18. Abstract 1725: Dual modality of EpiTAC bispecific degrader ADCs combines c-MET degradation with cytotoxic payload delivery to overcome limitations of current c-MET-targeted therapiesCancer Research · 2026
19. Towards efficient real-time video motion transfer via generative time series modelingMultimedia Tools and Applications · 2026
20. Abstract B053: Integrated real-time PK/PD cytometry and long-term exploratory immune profiling using Cyto-Chex and TokuKit in global trialsCancer Immunology Research · 2026